Amgen CDR (CAD Hedged)

Healthcare CA AMGN

25.54CAD
0.24(0.95%)

Last update at 2026-06-22T19:12:00Z

Day Range

25.5425.54

LowHigh

52 Week Range

20.2929.21

LowHigh

Fundamentals

Previous Close 25.30
Market Cap188792.80M
Volume200
P/E Ratio24.19
Dividend Yield36.43%
Revenue TTM0.00000M
Revenue Per Share TTM-
Gross Profit TTM 0.00000M
Diluted EPS TTM-

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Type	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Income before tax	8976.00M	4609.00M	7855.00M	7346.00M
Minority interest	-	-	-	-
Net income	7711.00M	4090.00M	6717.00M	6552.00M
Selling general administrative	6942.00M	7096.00M	6166.00M	5414.00M
Selling and marketing expenses	-	-	-	-
Gross profit	30328.00M	22966.00M	19775.00M	19917.00M
Reconciled depreciation	-	-	-	-
Ebit	-	-	-	-
Ebitda	-	-	-	-
Depreciation and amortization	-	-	-	-
Non operating income net other	-	-	-	-
Operating income	9080.00M	7473.00M	8122.00M	9644.00M
Other operating expenses	-	-	-	-
Interest expense	-	-	-	-
Tax provision	1265.00M	519.00M	1138.00M	794.00M
Interest income	-732.00000M	3301.00M	2637.00M	1406.00M
Net interest income	-	-	-	-
Extraordinary items	-	-	-	-
Non recurring	-	-	-	-
Other items	-	-	-	-
Income tax expense	-	-	-	-
Total revenue	36751.00M	33424.00M	28190.00M	26323.00M
Total operating expenses	27671.00M	25951.00M	20068.00M	16679.00M
Cost of revenue	6423.00M	10458.00M	8415.00M	6406.00M
Total other income expense net	-	-	-	-
Discontinued operations	-	-	-	-
Net income from continuing ops	-	-	-	-
Net income applicable to common shares	7711.00M	4090.00M	6717.00M	6552.00M
Preferred stock and other adjustments	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Type	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total assets	90586.00M	91839.00M	97154.00M	65121.00M
Intangible assets	22276.00M	27699.00M	32641.00M	16080.00M
Earning assets	-	-	-	-
Other current assets	4133.00M	419.00M	281.00M	355.00M
Total liab	81928.00M	85962.00M	90922.00M	61460.00M
Total stockholder equity	8658.00M	5877.00M	6232.00M	3661.00M
Deferred long term liab	-	-	-	-
Other current liab	-	-	-	-
Common stock	-	33533.00M	33070.00M	32514.00M
Capital stock	-	-	-	-
Retained earnings	-	-27590.00000M	-26549.00000M	-28622.00000M
Other liab	-	-	-	-
Good will	18680.00M	18637.00M	18629.00M	15529.00M
Other assets	12660.00M	9111.00M	8709.00M	5071.00M
Cash	-	-	-	-
Cash and equivalents	9129.00M	11973.00M	10944.00M	7629.00M
Total current liabilities	25489.00M	23099.00M	18392.00M	15687.00M
Current deferred revenue	-	-	-	-
Net debt	-	-	-	-
Short term debt	-	0.00000M	0.00000M	0.00000M
Short long term debt	-	-	-	-
Short long term debt total	-	-	-	-
Other stockholder equity	8658.00M	-66.00000M	-289.00000M	-231.00000M
Property plant equipment	7913.00M	7100.00M	6592.00M	6006.00M
Total current assets	29057.00M	29030.00M	30332.00M	22186.00M
Long term investments	-	-	-	-
Net tangible assets	-	-	-	-
Short term investments	-	-	0.00000M	1676.00M
Net receivables	9570.00M	6782.00M	7268.00M	5563.00M
Long term debt	50005.00M	56549.00M	63170.00M	37354.00M
Inventory	6225.00M	6998.00M	9518.00M	4930.00M
Accounts payable	-	-	-	-
Total permanent equity	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-
Accumulated other comprehensive income	-	-	-	-
Additional paid in capital	-	-	-	-
Common stock total equity	-	-	-	-
Preferred stock total equity	-	-	-	-
Retained earnings total equity	-	-	-	-
Treasury stock	-	-	-	-
Accumulated amortization	-	-	-	-
Non currrent assets other	-	-	-	-
Deferred long term asset charges	-	-	-	-
Non current assets total	-	-	-	-
Capital lease obligations	-	-	-	-
Long term debt total	50005.00M	56549.00M	63170.00M	37354.00M

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Type	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Investments	0.00000M	-	-	-
Change to liabilities	-	-	-	-
Total cashflows from investing activities	-1943.00000M	-1046.00000M	-26204.00000M	-6044.00000M
Net borrowings	-5000.00000M	-	-	-
Total cash from financing activities	-10859.00000M	-9415.00000M	21048.00M	-4037.00000M
Change to operating activities	-	-	-	-
Net income	7711.00M	4090.00M	6717.00M	6552.00M
Change in cash	-2844.00000M	1029.00M	3315.00M	-360.00000M
Begin period cash flow	11973.00M	-	-	-
End period cash flow	9129.00M	-	-	-
Total cash from operating activities	9958.00M	11490.00M	8471.00M	9721.00M
Issuance of capital stock	-	-	-	-
Depreciation	5167.00M	5592.00M	4071.00M	3417.00M
Other cashflows from investing activities	-85.00000M	50.00M	-25092.00000M	-5108.00000M
Dividends paid	5124.00M	4832.00M	4556.00M	4196.00M
Change to inventory	886.00M	-	-	-
Change to account receivables	-2676.00000M	-	-	-
Sale purchase of stock	0.00000M	-200.00000M	0.00000M	-6360.00000M
Other cashflows from financing activities	-52.00000M	-124.00000M	-72.00000M	-103.00000M
Change to netincome	-	-	-	-
Capital expenditures	1858.00M	1096.00M	1112.00M	936.00M
Change receivables	-	-	-	-
Cash flows other operating	-	-	-	-
Exchange rate changes	-	-	-	-
Cash and cash equivalents changes	-	-	-	-
Change in working capital	-1978.00000M	2365.00M	-484.00000M	-733.00000M
Stock based compensation	494.00M	-	-	-
Other non cash items	149.00M	-	-	-
Free cash flow	8100.00M	-	-	-

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company	Change (CAD)	Price (CAD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
AMGN Amgen CDR (CAD Hedged)	0.24 0.95%	25.54	24.19	15.65	5.06	21.36	6.30	13.69
NOVO Novo Nordisk CDR (CAD Hedged)	0.70 3.68%	19.70	3.31	3.54	1.10	1.74	3.88	7.66
MRK Merck CDR (CAD Hedged)	0.16 0.62%	25.84	15.70	22.32	4.40	5.36	4.81	11.07
GILD Gilead Sciences CDR (CAD Hedged)	-0.25 0.98%	25.30	19.51	15.04	5.62	7.21	6.14	13.31
SNY Sanofi CDR (CAD Hedged)	0.12 0.64%	18.92	3.25	1.53	0.34	0.22	2.33	8.73

Reports Covered

View All

Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen CDR (CAD Hedged)

One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799

805 447 1000
https://www.amgen.com
Employees : 28000

Key Executives

Name	Title	Year Born
Mr. Robert A. Bradway	Chairman, CEO & President	1963
Mr. Peter H. Griffith	Executive VP & CFO	1959
Dr. David M. Reese M.D.	Executive VP & CTO	1963
Mr. Murdo Gordon	Executive Vice President of Global Commercial Operations	1967
Dr. James E. Bradner M.D.	Executive Vice President of Research & Development	1972
Mr. Esteban Santos	Executive Vice President of Operations	1968
Mr. Matthew C. Busch	Chief Accounting Officer & VP of Finance	1975
Mr. Scott Skellenger	Senior VP & Chief Information Officer	NA
Mr. Howard Y. Chang M.D., Ph.D.	Senior VP of Global Research & Chief Scientific Officer	NA
Casey Capparelli	Executive Director of Investor Relations	NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.